Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AHS Cancer Control Alberta
This study may lead to the identification of additional investigations that can monitor for signs of disease progression in active surveillance protocols. This can directly benefit patients by providing them with greater confidence that their disease is being accurately monitored. In addition, this study may be beneficial to the general management of prostate cancers by adding to our knowledge of these investigations characterizing prostate cancers.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically proven adenocarcinoma of the prostate
Registration must occur within 16 weeks of last biopsy
History and physical exam (including DRE) within 8 weeks prior to registration
Patients must have indolent prostate cancer including all of the following: Low risk prostate cancer, less or equal to 50 % of core biopsies involved with disease, and less or equal to three biopsies involved with disease
Patients must have a minimum of six biopsies (sextant) at registration
PSA test within 8 weeks registration
Creatinine level below 100 umol/L within 8 weeks of registration
Patients must have no contraindications to MRI scans
No history of previous malignancies except non-melanoma skin tumors or other malignancies with a greater than 5 year life expectancy
Patients must be reliable for follow up
You may not be if
Patient does not have histologically-proven adenocarcinoma of the prostate
Last biopsy greater than 16 weeks prior to registration
History and physical exam (including DRE) greater that 8 weeks prior to registration
Patient does not have indolent disease
Patient has less than six sextant biopsies at registration
PSA test done greater than 8 weeks from registration
Creatinine level greater than 100 umol/L within 8 weeks of registration
Contraindications to MRI scans
History of previous malignancies other than non-melanoma skin tumors or other malignancies with a greater than 5 year life expectancy
Patients that are not reliable for follow up
Clareo Health | Biological Investigations in Active Surveillance (BIAS) IGAR 2008 I 19 in Prostate Cancer Using High Field MRI (3 Tesla), PET, and Biomarkers
